Mean FVC change in TTI-101-treated patients was -15mL; less of a decline when compared to the REVERT placebo (-22mL) and historical placebo groups from comparable IPF trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback